⁍ Novavax said last week its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus.
⁍ The company expects to be able to produce well over 2 billion doses of its vaccine annually overall.
– Last week, Novavax announced positive results from a small, early-stage clinical trial of its vaccine against coronavirus. Now, the company says it’s on track to meet the US demand for its vaccine as high as 600 million doses by 2021, reports Reuters. That’s up from the 500 million to 600 million doses the company previously estimated it would be able to produce, based on its capacity to make vaccines for respiratory syncytial virus and coronavirus. COVID-19 is being developed by Novavax in collaboration with the National Institutes of Health.
Source: https://www.reuters.com/article/health-cornavirus-novavax-vaccine/novavax-says-expects-it-can-meet-us-covid-19-vaccine-demand-in-2021-idUSL1N2FC1VA